Table of Content

1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency

2. Research Methodology
2.1. Research Process
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Market Size Estimation
2.3.1.1. Bottom-up Approach
2.3.1.2. Top-down Approach
2.3.1.3. Growth Forecast
2.3.2. Market Share Analysis
2.4. Assumptions for the Study
2.5. Limitations for the Study

3. Executive Summary

4. Market Insights
4.1. Market Overview
4.2. Drivers
4.2.1. Rising Awareness of Personalized Healthcare
4.2.2. Delay in Drug Development and the Consequent Increase in Development Costs
4.2.3. Growing Burden of Chronic Diseases
4.2.4. Shift toward Value-based Care
4.2.5. Rapidly Growing Big Data in the Healthcare Sector
4.3. Restraints
4.3.1. Reluctance to Rely on Real-world Data Studies
4.4. Opportunities
4.4.1. Emerging Economies
4.4.2. Rising Focus on End-to-end RWE Services
4.5. Challenges
4.5.1. Lack of Standardized Methodologies for Developing Real-world Data Solutions
4.6. Key Market Trends
4.6.1. Growing Adoption of RWD in Drug Development and Commercialization
4.6.2. Rising Number of Consolidations
4.7. The Impact of COVID-19 on the Real-world Data Market

5. Global Real-world Data Market: Regulatory Analysis
5.1. Introduction
5.2. North America
5.3. Europe
5.4. Asia-Pacific
5.5. Rest of the World

6. Global Real-world Data Market, by Pricing Model
6.1. Introduction
6.2. Pay-per-patient Record (Volume-based Pricing)
6.3. Pay-per-usage (Value-based Pricing)
6.4. Annual Subscription

7. Global Real-world Data Market, by Source
7.1. Introduction
7.2. EMR/EHR/Clinical Data
7.3. Claims & Billing Data
7.4. Pharmacy Data
7.5. Product/Disease Registries Data
7.6. Genomics Data
7.7. Other Sources

8. Global Real-world Data Market, by Application
8.1. Introduction
8.2. Market Access & Reimbursement/Coverage Decision
8.3. Drug Development & Approvals
8.3.1. Oncology
8.3.2. Neurology
8.3.3. Immunology
8.3.4. Cardiovascular Diseases
8.3.5. Other Therapeutic Areas
8.4. Medical Device Development & Approvals
8.5. Post-market Surveillance
8.6. Clinical & Regulatory Decision-Making

9. Global Real-world Data Market, by End User
9.1. Introduction
9.2. Pharmaceutical, Biotechnology, and Medical Device Companies
9.3. Healthcare Payers
9.4. Healthcare Providers
9.5. Other End Users

10. Real-world Data Market, by Geography
10.1. Introduction
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.3. Europe
10.3.1. U.K.
10.3.2. Germany
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Rest of Europe (RoE)
10.4. Asia-Pacific
10.4.1. Japan
10.4.2. China
10.4.3. India
10.4.4. South Korea
10.4.5. Taiwan
10.4.6. Singapore
10.4.7. Rest of Asia-Pacific (RoAPAC)
10.5. Latin America
10.6. Middle East & Africa

11. Competitive Landscape
11.1. Introduction
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Market Share Analysis (2021)
11.4.1. IQVIA Holdings Inc. (U.S.)
11.4.2. ICON plc (Ireland)
11.4.3. PPD Inc. (U.S.)

12. Company Profiles (Business Overview, Financial Overview, Solution Portfolio, Strategic Developments)
12.1. Clinigen Group plc
12.2. Cognizant Technology Solutions Corporation
12.3. Elevance Health, Inc.
12.4. Flatiron Health, Inc.
12.5. ICON plc
12.6. IQVIA Holdings Inc.
12.7. Oracle Corporation
12.8. PAREXEL International Corporation
12.9. PerkinElmer, Inc.
12.10. PPD Inc. (Subsidiary of Thermo Fisher Scientific Inc.)
12.11. SAS Institute Inc.
12.12. UnitedHealth Group Incorporated

13. Appendix
13.1. Questionnaire
13.2. Available Customization



List of Figures

List of Figures
Figure 1 Key Stakeholders
Figure 2 Research Process
Figure 3 Key Secondary Sources
Figure 4 Primary Research Techniques
Figure 5 Key Executives Interviewed
Figure 6 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 7 Market Size Estimation
Figure 8 Global Real-world Data Market, by Source, 2022 Vs. 2029 (USD Million)
Figure 9 Global Real-world Data Market, by Application, 2022 Vs. 2029 (USD Million)
Figure 10 Global Real-world Data Market, by End User, 2022 Vs. 2029 (USD Million)
Figure 11 Global Real-world Data Market, by Geography
Figure 12 Market Dynamics
Figure 13 Percentage of Personalized Medicines Approved (2015–2020)
Figure 14 U.S.: Number of People With Chronic Conditions (2000–2030)
Figure 15 Asia-Pacific: Percent Share of Global Clinical Trial Activities (2012–2020)
Figure 16 Global Real-world Data Market Size, by Source, 2022 Vs. 2029 (USD Million)
Figure 17 U.S.: Number of E-Prescriptions, 2013–2020 (In Billion)
Figure 18 Global Real-world Data Market Size, by Application, 2022 Vs. 2029 (USD Million)
Figure 19 Estimated Number of New Cancer Cases, by Region, 2020–2040 (In Million)
Figure 20 Global Real-world Data Market Size, by End User, 2022 Vs. 2029 (USD Million)
Figure 21 Pharmaceutical R&D Spending, 2012–2026 (USD Billion)
Figure 22 Global Real-world Data Market Size, by Region, 2022 Vs. 2029 (USD Million)
Figure 23 North America: Real-world Data Market Snapshot
Figure 24 Number of Novel Drugs Approved by the CDER (2010–2021)
Figure 25 Europe: Real-world Data Market Snapshot
Figure 26 Germany: Pharmaceutical R&D Expenditure, 2016–2020 (USD Million)
Figure 27 France: Share of the Population Aged 65 Years & Above (2010–2020)
Figure 28 Italy: Share of the Population Aged 65 Years and Above (2015–2020)
Figure 29 Spain: Pharmaceutical R&D Expenditure, 2016–2020 (USD Million)
Figure 30 Pharmaceutical R&D Expenditure in European Countries, 2016–2020 (USD Million)
Figure 31 Asia-Pacific: Real-world Data Market Snapshot
Figure 32 Japan: Number of People Below 65 Years of Age (2000–2050)
Figure 33 Key Growth Strategies Adopted by Leading Players (2018–2022)
Figure 34 Real-world Data Market: Competitive Benchmarking, by Geography
Figure 35 Market Share Analysis: Real-world Data Industry (2021)
Figure 36 Financial Overview (2019–2021): IQVIA Holdings Inc.
Figure 37 Financial Overview (2018–2020): PPD Inc.
Figure 38 Financial Overview (2019–2021): ICON plc
Figure 39 Financial Overview (2019–2021): UnitedHealth Group Incorporated
Figure 40 Financial Overview (2019–2021): Oracle Corporation
Figure 41 Financial Overview (2020–2021): SAS Institute Inc.
Figure 42 Financial Overview (2019–2021): Elevance Health, Inc.
Figure 43 Financial Overview (2019–2021): Clinigen Group plc
Figure 44 Financial Overview (2019–2021): Cognizant Technology Solutions Corporation
Figure 45 Financial Overview (2019–2022): PerkinElmer, Inc.